GLP-3 (Glucagon-Like Peptide-3)

GLP-3 is a peptide hormone belonging to the glucagon family, primarily associated with gastrointestinal motility and gut hormone regulation. It is a critical element in the study of gut physiology, appetite regulation, and metabolic processes, often explored in the context of preclinical research for potential mechanistic insights.

Research Context

GLP-3 is synthesized in the intestinal L-cells and plays a key role in coordinating intestinal transit, glucose metabolism, and satiety signaling. Its physiological functions are well-documented in animal models and human studies focusing on digestive processes, including postprandial responses and motility regulation. In research settings, GLP-3 is frequently investigated for its implications in gastrointestinal disorders, metabolic homeostasis, and as a marker for gut health.

Research Overview

GLP-3 research primarily centers on its role in modulating gut motility, appetite suppression, and insulin secretion. Studies have explored synthetic analogs of GLP-3 for therapeutic development, though these are beyond the scope of this product description. This peptide is often used in preclinical investigations to study its effects on intestinal function, particularly in conditions such as irritable bowel syndrome (IBS) and diabetes-related gut dysmotility. Due to its regulatory pathways, GLP-3 is a valuable tool for studying gastrointestinal pharmacology and metabolic interactions.

Key Research Focus Areas

• Gastrointestinal Motility: Investigation of GLP-3’s effects on intestinal contractions, transit time, and coordination of gut motility in preclinical models.
• Appetite Regulation: Analysis of GLP-3’s role in suppressing hunger signals and its potential influence on satiety mechanisms in both healthy and disease states.
• Metabolic Homeostasis: Examination of GLP-3’s interactions with glucose metabolism, insulin sensitivity, and endocrine responses postprandially.
• Gut Health and Disorders: Exploration of GLP-3 in conditions such as IBS, inflammatory bowel disease (IBD), and diabetic enteropathy through preclinical studies.
• Gut-Hormone Signaling: Study of GLP-3’s signaling pathways and interactions with other intestinal hormones, including GLP-1 and peptide YY (PYY).

Safety and Compliance Statement

This peptide is intended solely for use in accredited research facilities under the supervision of qualified personnel. GLP-3 should only be handled in accordance with established biosafety protocols, including proper storage, labeling, and disposal procedures. Researchers must adhere to regulatory guidelines governing peptide use and ensure compliance with institutional review boards and ethical standards applicable to their institution.

For research use only. Not for human or animal consumption.